B
BeyondSpring Inc. (BYSI)
NCM – Real Time Price. Currency in USD
0.74
-0.05 (-6.16%)
Market open: Aug 12, 2026, 3:37 PM EDT
0.79
+0.00 (0.01%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.74
-0.05 (-6.16%)
Market open: Aug 12, 2026, 3:37 PM EDT
0.79
+0.00 (0.01%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
| Name | Position |
|---|---|
| Dr. John Mao Ph.D. | Senior Vice President of Development |
| Dr. June Lu Ph.D. | Chief Scientific Officer |
| Dr. Lan Huang Ph.D. | Co-Founder & Chair of the Board |
| Mr. Min Qiu | Chief Executive Officer |
| Ms. Joy Jia | Vice President of Finance |
| Ms. Li Na | Chief Financial Officer |
| Stephen Kilmer | Head of Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-06-29 | 8-K/A | f8ka_062926.htm |
| 2026-06-04 | 8-K | f8k_060426.htm |
| 2026-05-13 | 8-K | f8k_051326.htm |
| 2026-05-13 | 10-Q | bysi20260331_10q.htm |
| 2026-03-25 | 8-K | f8k_032526.htm |
| 2026-03-25 | 10-K | bysi20251231_10k.htm |
| 2025-12-15 | 8-K | f8k_121525.htm |
| 2025-11-21 | 8-K | f8k_111925.htm |
| 2025-11-12 | 8-K | f8k_111225.htm |
| 2025-11-12 | 10-Q | bysi20250930_10q.htm |